Amgen Said to Boost Bid for Onyx to $130 a Share

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

Aug. 6 (Bloomberg) -- Amgen, the drugmaker in pursuit of Onyx Pharmaceuticals, boosted its offer for the company to $130 a share, according to a person familiar with the matter. Olivia Sterns reports on Bloomberg Television's "Street Smart." (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change